TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20067950

Group type: COMPARATOR
Intervention: Stroke patients walking in a virtual environment (VE) with translational optic flows (OFs) from different directions.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Healthy participants walking in a virtual environment (VE) with translational optic flows (OFs) from different directions.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (stroke patients and healthy participants) walking in a virtual environment (VE) with translational optic flows (OFs) from different directions.
Number of subjects: 21
Study: 18984559

Group type: EXPERIMENTAL
Intervention: Internet-delivered intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 190
Study: 16061320

Group type: EXPERIMENTAL
Intervention: Retrofitted insulation
Number of subjects: 1352
Study: 12197863

Group type: EXPERIMENTAL
Intervention: Motivational interview
Number of subjects: 160

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 160
Study: 10983541

Group type: EXPERIMENTAL
Intervention: Antenatal counselling sessions
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Antenatal counselling sessions with husbands involved
Number of subjects: 300
Study: 7881239

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (core temperatures near 34 degrees C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active cooling (core temperatures approaching 32 degrees C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forced air cooling method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active rewarming post-hypothermia
Number of subjects: 0
Study: 2268740

Group type: EXPERIMENTAL
Intervention: Oyster shell electrolysate (OSE) 900 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 12
Study: 707353

Group type: EXPERIMENTAL
Intervention: Zn supplement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31825609

Group type: EXPERIMENTAL
Intervention: Debiased data splits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomly split held-out sets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Debiased data
Number of subjects: 0
Study: 30925739

Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 108

Group type: COMPARATOR
Intervention: PVC
Number of subjects: 108
Study: 28780466

Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 (GC80)
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 (GC50)
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC6 (GCb6)
Number of subjects: 1363
Study: 26037199

Group type: EXPERIMENTAL
Intervention: Sinetrol® XPur (900 mg daily for 12 weeks)
Number of subjects: 0
Study: 23770157

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 9 μg/kg
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 18 μg/kg
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 18 μg/kg (re-treated patients)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 18 μg/kg (CD25 low-expression patients)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) (patients with capillary leak syndrome)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) (patients without capillary leak syndrome)
Number of subjects: 307
Study: 22303710

Group type: EXPERIMENTAL
Intervention: Methimazole combined with Radix Astragali (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Methimazole (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 80
Study: 18071342

Group type: EXPERIMENTAL
Intervention: Liquid product
Number of subjects: 157

Group type: COMPARATOR
Intervention: Semi-liquid product
Number of subjects: 157

Group type: COMPARATOR
Intervention: Semi-solid product
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Liquid product (laboratory setting)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Semi-solid product (laboratory setting)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Liquid product (standardized eating rate)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Semi-solid product (standardized eating rate)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Liquid product (not controlled)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Semi-solid product (not controlled)
Number of subjects: 157
Study: 16446219

Group type: EXPERIMENTAL
Intervention: Des-Arg9-bradykinin at concentrations of 5.4 x 10(-9), 5.4 x 10(-8), 5.4 x 10(-7), and 1.6 x 10(-6) mol/liter
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acetylcholine at concentrations of 10(-8), 10(-7), and 10(-6) mol/liter
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control subjects (no specific intervention mentioned)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Heart transplant patients (no specific intervention mentioned)
Number of subjects: 22
Study: 12639582

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Minor surgical procedure
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Oral medication
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Hormonal intrauterine system
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Pre-treatment preference for hysterectomy
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Pre-treatment preference for conservative option
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Factors influencing treatment choice
Number of subjects: 383
Study: 10708256

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study: 9094872

Group type: EXPERIMENTAL
Intervention: Dephytinized infant cereal (0.01% phytic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cereal with native phytic acid (0.08% phytic acid)
Number of subjects: 0
Study: 1283590

Group type: EXPERIMENTAL
Intervention: verapamil 240mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: captopril 25mg twice daily
Number of subjects: 20
Study: 3571940

Group type: EXPERIMENTAL
Intervention: Methylamphetamine (15 mg, intravenous)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (sterile water, intravenous)
Number of subjects: 21
Study: 31009528

Group type: EXPERIMENTAL
Intervention: Smoking cessation behavioral counseling without weight management counseling
Number of subjects: 2540

Group type: EXPERIMENTAL
Intervention: Smoking cessation behavioral counseling with weight management counseling
Number of subjects: 2540

Group type: COMPARATOR
Intervention: Control calls (counseling calls)
Number of subjects: 2540

Group type: EXPERIMENTAL
Intervention: Smoking cessation pharmacotherapy
Number of subjects: 2540
Study: 29364489

Group type: EXPERIMENTAL
Intervention: Hindlimb suspension (HS) for 2 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 14
Study: 27005405

Group type: EXPERIMENTAL
Intervention: liraglutide 3.0mg
Number of subjects: 359

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 359
Study: 24685072

Group type: EXPERIMENTAL
Intervention: Telephone Support Intervention (TSI)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Telephone Support Intervention + Uterine Artery Doppler Screening (TSI + UADS)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Standard antenatal care (Control)
Number of subjects: 840
Study: 22612463

Group type: EXPERIMENTAL
Intervention: Family group cognitive‐behavioral (FGCB) intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Written information (WI) comparison condition
Number of subjects: 180
Study: 20117594

Group type: EXPERIMENTAL
Intervention: Experimental group (assigned shoes based on foot shape)
Number of subjects: 1955

Group type: COMPARATOR
Intervention: Control group (received stability shoe regardless of plantar shape)
Number of subjects: 1955
Study: 16485047

Group type: EXPERIMENTAL
Intervention: Lisinopril therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12851558

Group type: EXPERIMENTAL
Intervention: Particle repositioning maneuver
Number of subjects: 40
Study: 11106716

Group type: EXPERIMENTAL
Intervention: 180 microg of peginterferon alfa‐2a once weekly
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 90 microg of peginterferon alfa‐2a once weekly
Number of subjects: 271

Group type: COMPARATOR
Intervention: 3 million units of interferon alfa‐2a three times weekly
Number of subjects: 271
Study: 9053508

Group type: EXPERIMENTAL
Intervention: Monthly regimen of IV LV 20 mg/m2 plus bolus 5‐FU 425 mg/m2 for 5 days every 4 weeks
Number of subjects: 433

Group type: COMPARATOR
Intervention: Bimonthly regimen of IV LV 200 mg/m2 as a 2-hour infusion followed by bolus 5‐FU 400 mg/m2 and 22-hour infusion 5‐FU 600 mg/m2 for 2 consecutive days every 2 weeks
Number of subjects: 433
Study: 8372720

Group type: EXPERIMENTAL
Intervention: Bucillamine (Bu) 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bucillamine (Bu) 3200 mg (single administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3606739

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 6027

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6027
Study: 30872330

Group type: EXPERIMENTAL
Intervention: Multicomponent, comprehensive school health program delivered by lay field-workers
Number of subjects: 3033

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3033
Study: 29565771

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower-Body Negative Pressure (LBNP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: α1-receptor blockade via oral prazosin (0.05 mg/kg body wt)
Number of subjects: 10
Study: 27734482

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study: 24232445

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St John's wort)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 22476569

Group type: EXPERIMENTAL
Intervention: Recognition condition, excluding 15 questions
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Recall condition
Number of subjects: 270
Study: 22192944

Group type: EXPERIMENTAL
Intervention: Monthly visits by Community Health Workers (CHWs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no monthly visits by CHWs)
Number of subjects: 30
Study: 18586993

Group type: EXPERIMENTAL
Intervention: BCM care
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study: 17371478

Group type: EXPERIMENTAL
Intervention: Meal A (230 kcal, 0.6 g lipid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Meal B (220 kcal, 5 g lipid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Meal C (474 kcal, 19 g lipid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Meal D (837 kcal, 44 g lipid)
Number of subjects: 24
Study: 12928050

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 141
Study: 10666525

Group type: EXPERIMENTAL
Intervention: Multidisciplinary pain centre treatment (MPT), n=63
Number of subjects: 189

Group type: COMPARATOR
Intervention: General practitioner treatment (GP-group), n=63
Number of subjects: 189

Group type: COMPARATOR
Intervention: Waiting list group (WL-group), n=63
Number of subjects: 189

Group type: COMPARATOR
Intervention: MPT and GP-groups
Number of subjects: 189
Study: 10179602

Group type: EXPERIMENTAL
Intervention: Computerized color visual field analysis using 264 colored patches displayed on a PC screen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normals
Number of subjects: 0
Study: 8378100

Group type: EXPERIMENTAL
Intervention: Positive Emotion Induction (PEI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brief Relaxation (BR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-instruction (Control)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Social Demand (Control)
Number of subjects: 80
Study: 3730264

Group type: EXPERIMENTAL
Intervention: Combination of 200 micrograms salbutamol and 200 micrograms oxitropium bromide
Number of subjects: 0

Group type: COMPARATOR
Intervention: 200 micrograms salbutamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 micrograms salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose salbutamol treatment
Number of subjects: 0
Study: 29357943

Group type: EXPERIMENTAL
Intervention: Individualized feedback letters based on accelerometer data
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 100
Study: 26951845

Group type: EXPERIMENTAL
Intervention: PEITC (10 mg in 1 mL of olive oil, 4 times per day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 23532433

Group type: EXPERIMENTAL
Intervention: FemoSeal® VCD
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 1001
Study: 23575741

Group type: EXPERIMENTAL
Intervention: escitalopram (ESC) 10-20 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 20205227

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate (CHO) treatment
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate (CHO) treatment (in subgroup without epidural blockade or laparoscopic surgery)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo treatment (in subgroup without epidural blockade or laparoscopic surgery)
Number of subjects: 142
Study: 18769684

Group type: EXPERIMENTAL
Intervention: Trendelenburg position at 30 degrees plus 5 manual inflations of the lungs
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard passive deflation of residual abdominal carbon dioxide through the cannula
Number of subjects: 116
Study: 16889546

Group type: EXPERIMENTAL
Intervention: CMV‐IVIG
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 12912805

Group type: EXPERIMENTAL
Intervention: Aneurysmal wall from patients with cerebral aneurysms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cortical arterial wall
Number of subjects: 0
Study: 10731405

Group type: EXPERIMENTAL
Intervention: Original images
Number of subjects: 71

Group type: COMPARATOR
Intervention: Compression ratio 6:1
Number of subjects: 71

Group type: COMPARATOR
Intervention: Compression ratio 10:1
Number of subjects: 71

Group type: COMPARATOR
Intervention: Compression ratio 16:1
Number of subjects: 71
Study: 8800106

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for acute myocardial infarction
Number of subjects: 481
Study: 1503488

Group type: EXPERIMENTAL
Intervention: 254-S (80 to 100 mg/m2, administered at least 2 times at 4-week intervals)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 254-S plus vindesine
Number of subjects: 62

Group type: COMPARATOR
Intervention: cisplatin plus vindesine
Number of subjects: 62
Study: 6394228

Group type: EXPERIMENTAL
Intervention: Factor XIII concentrate (750 IU for 3 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Factor XIII concentrate (1500 IU for 3 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no factor XIII substitution)
Number of subjects: 61
Study: 31872905

Group type: EXPERIMENTAL
Intervention: Fantastical television content
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-fantastical television content
Number of subjects: 80
Study: 31867651

Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction to 0.04 mg nicotine/g of tobacco
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction to 0.04 mg nicotine/g of tobacco
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 1250
Study: 28330941

Group type: EXPERIMENTAL
Intervention: Nurse-driven clinical pathway (weaning salbutamol frequency using an asthma scoring tool)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard care (physicians weaning salbutamol frequency)
Number of subjects: 113
Study: 25864950

Group type: EXPERIMENTAL
Intervention: Continuous D₂ blockade (estimated trough D2 blockade of >65%)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-continuous blockade (estimated peak level of >65% with an estimated trough level of <65%)
Number of subjects: 68
Study: 23805925

Group type: EXPERIMENTAL
Intervention: 8-week gentle yoga intervention
Number of subjects: 12
Study: 21665108

Group type: EXPERIMENTAL
Intervention: Backnobber II device
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (non-treated MTrP)
Number of subjects: 28
Study: 19845495

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 1354

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1354

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (in patients aged >65 years)
Number of subjects: 1354

Group type: COMPARATOR
Intervention: Standard therapy (in patients aged >65 years)
Number of subjects: 1354
Study: 16475483

Group type: EXPERIMENTAL
Intervention: Quantitative EEG assessment post-liver transplantation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Quantitative EEG assessment post-liver transplantation (without complications)
Number of subjects: 14
Study: 14766715

Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 g ml(‐1)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 g ml(‐1)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 g ml(‐1)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 7.5 g ml(‐1)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Dextrose concentrations (10, 20, 30, 50, and 80 g ml(‐1)) added to 5 g ml(‐1) solutions
Number of subjects: 1250
Study: 11176015

Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 9290986

Group type: EXPERIMENTAL
Intervention: Sucralfate administration
Number of subjects: 20
Study: 8318480

Group type: EXPERIMENTAL
Intervention: Topical ketanserin 0.5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3013495

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (2 g/day for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30988478

Group type: EXPERIMENTAL
Intervention: Framing intervention that highlights incompatibility of food marketing with adolescent values
Number of subjects: 0
Study: 28506314

Group type: EXPERIMENTAL
Intervention: ILMOD group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 25226048

Group type: COMPARATOR
Intervention: SnF2 gel 2500 ppm F (5 min) every third day
Number of subjects: 8

Group type: COMPARATOR
Intervention: NaF toothpaste 5000 ppm F (5 min every third day and 2 min other days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: NaF toothpaste 1450 ppm F (2 min every day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no fluoride treatment)
Number of subjects: 8
Study: 22860989

Group type: EXPERIMENTAL
Intervention: Lichen sclerosus group (n=48)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (n=44)
Number of subjects: 92
Study: 21420555

Group type: EXPERIMENTAL
Intervention: NASHA Dx (transanal submucosal injections)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 206
Study: 19797376

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 325

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 325
Study: 17022207

Group type: EXPERIMENTAL
Intervention: Monte Carlo dose engine (MCDE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pinnacle‐CS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Helax‐CC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Helax‐PB
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All algorithms (MCDE, Pinnacle‐CS, Helax‐CC, Helax‐PB)
Number of subjects: 10
Study: 15386949

Group type: EXPERIMENTAL
Intervention: Acute dipterex poisoning (ADP) patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy adult volunteers (HAVs)
Number of subjects: 50
Study: 12616820

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy performed in 43 clinics and departments
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Splenectomy performed in case of cardiac or upper third tumors
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Splenectomy performed in case of suspicious hilar lymph nodes
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined, extended operation performed if tumorous infiltrates surrounding organs
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined, extended operation performed as palliation
Number of subjects: 47
Study: 9834040

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (25 mg) as a CYP1A2 inhibitor
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketoconazole (100 mg) as a CYP3A4 inhibitor
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ropivacaine alone (40 mg)
Number of subjects: 12
Study: 8590556

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control situation (no treatment)
Number of subjects: 20
Study: 2636699

Group type: EXPERIMENTAL
Intervention: Desmopressin nasal spray
Number of subjects: 10

Group type: COMPARATOR
Intervention: Desmopressin tablets
Number of subjects: 10
Study: 1098705

Group type: EXPERIMENTAL
Intervention: Synthetic anticholinergic drug (SCH 10000)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10